Search

Your search keyword '"Marchei E"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Marchei E" Remove constraint Author: "Marchei E"
142 results on '"Marchei E"'

Search Results

6. Targeted screening and quantification of synthetic cathinones and metabolites in hair by UHPLC-HRMS.

9. Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy

11. Assessment of prenatal exposure to ethanol by meconium analysis: results of an Italian multicenter study

13. Is GHB-glucuronide useful as a biomarker for the exogenous use of GHB?

26. The prevalence and changes of alcohol consumption across three trimesters of pregnancy assessed by ethyl glucuronide concentration in maternal hair and self-reports: a cross-sectional study.

27. Prevalence of Psychoactive Substance Use During Pregnancy in Argentine Women: A Pilot Study Testing Maternal Hair.

28. NPS-EQA PART I: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in oral fluid.

29. NPS-EQA PART II: Four years' experience in external quality assessment program in Italy for classical and new psychoactive substances analysis in hair.

30. OILVEQ: an Italian external quality control scheme for cannabinoids analysis in galenic preparations of cannabis oil.

31. Metabolic profile of N-ethylhexedrone, N-ethylpentedrone, and 4-chloromethcathinone in urine samples by UHPLC-QTOF-HRMS.

32. Alcohol Consumption Assessed by a Biomarker and Self-Reported Drinking in a Sample of Pregnant Women in the South of Europe: A Comparative Study.

33. Assessment of alcohol consumption in mexican pregnant women by hair testing of ethyl glucuronide.

34. The recurrent pathogenic Pro890Leu substitution in CLTC causes a generalized defect in synaptic transmission in Caenorhabditis elegans .

35. GC-MS/MS Determination of Synthetic Cathinones: 4-chloromethcathinone, N-ethyl Pentedrone, and N-ethyl Hexedrone in Oral Fluid and Sweat of Consumers under Controlled Administration: Pilot Study.

36. Synthetic cannabinoids use in a sample of opioid-use disorder patients.

37. New Psychoactive Substances Consumption in Opioid-Use Disorder Patients.

38. Prevalence of Licit and Illicit Drugs Use during Pregnancy in Mexican Women.

39. Assessment of licit and illicit drugs consumption during pregnancy by Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS) target screening in Mexican women hair.

40. New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona.

41. Clinical features and risk factors associated with prenatal exposure to drugs of abuse.

42. Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers.

43. Role of Neonatal Biomarkers of Exposure to Psychoactive Substances to Identify Maternal Socio-Demographic Determinants.

44. Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS.

45. [Clinical features and risk factors associated with prenatal exposure to drugs of abuse].

46. UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers.

47. Stability and Degradation Pathways of Different Psychoactive Drugs in Neat and in Buffered Oral Fluid.

49. Novel fast ultra-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) and extraction of ethylglucuronide in meconium samples.

50. Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry.

Catalog

Books, media, physical & digital resources